
A study evaluated the safety and efficacy of a single rectal dose of RBL (REBYOTA) in 793 participants with recurrent CDI (rCDI) across the US and Canada. Treatment-emergent adverse events (TEAEs) were reported by 47.3% of those receiving RBL, primarily mild to moderate gastrointestinal issues, with serious TEAEs occurring in 3.9%. At 8 weeks, the treatment success rate was 73.8%, and 91.0% of those achieving success maintained a clinical response at 6 months. The study, the largest of its kind, demonstrated that RBL was both safe and effective for preventing rCDI in patients with common comorbidities, supporting its use in a broad patient population.
Like
Save
Share